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The life history of cancer cells encompasses a series of genetic missteps in which normal cells are progressively transformed
into tumor cells that invade surrounding tissues and become malignant. Most prominent among the regulators disrupted in
cancer cells are two tumor suppressors, the retinoblastoma protein (RB) and the p53 transcription factor. Here, we discuss
interconnecting signaling pathways controlled by RB and p53, attempting to explain their potentially universal involvement in
the etiology of cancer. Pinpointing the various ways by which the functions of RB and p53 are subverted in individual tumors
should provide a rational basis for developing more refined tumor-specific therapies.
Transformation of cultured primary cells into tumorigenic vari-
ants is a multistep process, whereby each genetic change con-
fers a proliferative advantage (Hahn and Weinberg, 2002). The
evolution of cancer in living animals is considerably more com-
plex, since specific interactions between tumor cells and host
tissues are necessary for tumor angiogenesis, tissue invasion,
and metastasis.Yet, despite the existence of many forms of can-
cer and global changes in gene expression profiles observed in
cancer cells versus normal cells, a relatively small number of
essential alterations are shared by most, and perhaps all,
tumors (Hanahan and Weinberg, 2000). Such mutations can
disrupt normal growth control in response to environmental
cues, or can dismantle cell cycle checkpoints that otherwise
limit cell division or that induce cell suicide in response to DNA
damage or oncogene activation. RB and p53 are central to
these processes.
Starting and stopping the cell cycle
The proliferation of mammalian cells is normally determined by
extracellular signals that engage a program of gene expression
and protein regulation required for cell division (Sherr, 1996).
During the first gap phase (G1) of the cell division cycle, mito-
genic stimulation triggers the activity of key regulatory molecules
that initiate DNA synthesis (S phase), after which cells are com-
mitted to complete the cycle and divide. In early G1 phase, indi-
vidual D-type cyclins (D1, D2, and D3), induced in a cell lineage-
specific manner, assemble into holoenzyme complexes with one
of two catalytic subunits, the cyclin-dependent kinases Cdk4 and
Cdk6. These six holoenzymes exhibit similar biochemical func-
tions, and most investigations have focused on the prototypic
cyclin D1-Cdk4 complex. Transcription of the cyclin D1 gene, its
synthesis and assembly with Cdk4, and the stability and nuclear
retention of the holoenzyme depend strongly on receptor-medi-
ated Ras and phosphatidylinositol 3-kinase (PI3-K) signaling
(Marshall, 1999) (Figure 1). Persistent mitogenic stimulation
leads to progressive accumulation of cyclin D-dependent kinas-
es within the cell nucleus; here they collaborate with cyclin E-
Cdk2 to phosphorylate RB and RB family members p107 and
p130, canceling their growth inhibitory functions and facilitating
S phase entry.
The activities of cyclin D- and cyclin E-dependent kinases are
linked through the agency of the “Cip/Kip” family of Cdk inhibitors,
which include p27Kip1, p21Cip1, and p57Kip2 (Sherr and Roberts,
1999). Both p27Kip1 and p21Cip1 are potent inhibitors of cyclin E-
bound Cdk2, but, in living cells, are less effective in blocking the
enzymatic activity of cyclin D-bound Cdk4 (Soos et al., 1996;
Blain et al., 1997). Instead, the assembly, stability, and nuclear
retention of cyclin D1-Cdk4 complexes are facilitated by physical
association with Cip/Kip subunits (LaBaer et al., 1997; Cheng et
al., 1999; Alt et al., 2002; Muraoka et al., 2002) (Figure 1). These
features underscore an important interplay between Cdk4 and
Cdk2 during cell cycle entry. In quiescent cells, cyclin D1 levels
are low, cyclin D1-Cdk4 complexes do not form, and high levels
of p27Kip1 suppress cyclin E-Cdk2 activity. Mitogen stimulation
induces cyclin D1 and regulates its assembly with Cdk4, there-
by sequestering p27Kip1 and activating cyclin E-Cdk2 (Figure 2).
This pool of p27Kip1 remains bound to cyclin D1-Cdk4, whereas
the remainder is phosphorylated by cyclin E-Cdk2, triggering its
ubiquitination and degradation (Sheaff et al., 1997; Vlach et al.,
1997). Both G1 cyclin-dependent kinases can then collaborate
in phosphorylating and inactivating RB as cells approach the
G1 to S phase transition.
Cell cycle exit following mitogen withdrawal depends upon
a reversal of these processes. Cyclin D1 transcription is can-
celled, rapidly leading to destruction of the cyclin D1-Cdk4
holoenzyme. The liberated pool of p27Kip1 blocks cyclin E-Cdk2
activity, enabling unphosphorylated p27Kip1 to reaccumulate.
Inhibition of G1 cyclin-dependent kinases returns RB family
proteins to their hypophosphorylated active state, and cells
exit the cycle.
The RB-E2F connection
RB, p130, and p107 physically interact with many proteins, but
their binding to members of the E2F family of transcription fac-
tors appears to be central to their role in governing DNA replica-
tion (Dyson, 1998; Nevins, 2001; Trimarchi and Lees, 2002).
Complexes between RB family members and various E2Fs
actively repress gene expression by recruiting histone deacety-
lases (HDACs) and other chromatin remodeling factors to E2F-
responsive promoters (Harbour and Dean, 2000; Rayman et al.,
2002; Ogawa et al., 2002). However, Cdk-mediated phosphory-
lation of RB family members prevents their association with
both HDACs and E2Fs and enables E2F-dependent gene
expression (Figure 2). Importantly, E2Fs coordinately regulate
genes necessary for DNA replication, including those coding for
enzymes required for DNA metabolism and synthesis, as well
as cyclins E and A. Hence, the active hypophosphorylated
forms of RB family members block entry into S phase by inhibit-
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ing the E2F transcriptional program.
RB itself is nonessential for cell cycle control (Jacks, 1996),
and its actual role in governing cell cycle progression in different
physiologic settings remains unresolved. For example, recruit-
ment of HDACs to E2F-responsive promoters in normal fibrob-
lasts is largely controlled by p107 and p130 during the cell cycle
(Rayman et al., 2002), raising the possibility that RB contributes
to gene repression only under certain conditions, such as when
cells differentiate or become senescent (Sellers et al., 1998;
Lipinski and Jacks, 1999; Thomas et al., 2001). RB preferential-
ly binds to a subset of E2Fs, whereas p107 and p130 associate
with others (Dyson, 1998; Nevins, 2001; Trimarchi and Lees,
2002). Apart from E2Fs, RB also interacts with other transcrip-
tion factors that govern cell differentiation (Dyson, 1998; Sellers
et al., 1998; Lipinski and Jacks, 1999; Thomas et al., 2001).
Because mutations affecting p107 and p130 occur rarely, if at
all, in cancer, such distinctions are key to understanding RB’s
tumor suppressor function.
The INK4 family
Four INK4 proteins (p16INK4a, p15INK4b, p18INK4c, and p19INK4d)
specifically inhibit the activity of cyclin D-dependent kinases to
prevent phosphorylation of RB family proteins (Ruas and
Peters, 1998; Sherr and Roberts, 1999; Roussel, 1999; Ortega
et al., 2002). Disruption of individual Ink4 genes in the mouse
germline and studies with mouse embryo fibroblasts (MEFs)
have not revealed profound cell cycle anomalies in Ink4-defi-
cient cells. That all four strains of Ink4 null mice are born at the
expected Mendelian ratio and develop normally also implies
that no one family member is essential for cell cycle control
(Roussel, 1999; Ortega et al., 2002). Yet, mice lacking p16Ink4a,
in particular, are tumor prone and develop a wide spectrum of
cancers, particularly after exposure to chemical carcinogens or
X-rays (Serrano et al., 1996; Krimpenfort et al., 2001; Sharpless
et al., 2001). Whereas Ink4c and Ink4d are broadly expressed
during mouse development and in adult tissues, expression of
Ink4a and Ink4b is limited in utero and is sporadic as mice age
(Zindy et al., 1997). Therefore, p18Ink4c and p19Ink4d appear to be
primarily dedicated to developmental roles in cell cycle control,
whereas p16Ink4a and p15Ink4b have more restricted functions.
Both p16Ink4a and p15Ink4b are selectively induced when pri-
mary MEFs are explanted into culture (Zindy et al., 1997). A
progressive increase in p16Ink4a levels as such cells are serially
passaged correlates with their diminishing proliferative capacity,
arguing for a role for p16Ink4a in cellular senescence (Alcorta et
al., 1996; Hara et al., 1996; Zindy et al., 1997). Stress stemming
from a nonphysiologic cell culture environment generates sig-
nals that activate p16Ink4a synthesis (Sherr and DePinho, 2000),
but its induction can be retarded, or even eliminated, by chang-
ing conditions in which primary cells are grown (Ramirez et al.,
2001). This argues that p16Ink4a plays a specialized role within
the Ink4 family in countering certain signals that abnormally
drive cell proliferation, a checkpoint function that is eroded in
tumor cells.
The “RB pathway” and cancer
The biochemical activities of the INK4 proteins, cyclin D-depen-
dent kinases, and RB family proteins highlight a pathway con-
trolling G1 phase progression:
INK4 proteins | cyclin D-dependent kinases |
RB family proteins
There is now compelling evidence that particular components of
Figure 1. Cyclin D1 activity is regulated by Ras 
Ras-dependent signaling through a pathway (gray shading) involving Raf, MEK, and ERK (extracellular signal-regulated kinases) activates transcription fac-
tors (e.g., AP1) that upregulate cyclin D1 transcription. Once translated, the assembly of cyclin D1 into active holoenzyme complexes containing Cdk4 and
a Cip/Kip protein (p27Kip1 is shown) requires signaling though the same Ras pathway (orange shading). Assembly of cyclin D1 with Cdk4, import of stable
complexes into the cell nucleus, and their persistence depend upon Cip/Kip proteins. Glycogen synthase kinase-3β (GSK-3β) can phosphorylate cyclin D1
to trigger its nuclear export, ubiquitination, and proteasomal degradation. A distinct Ras-dependent pathway (blue shading) that includes phosphatidyli-
nositol 3-kinase (PI3-K) and the AKT kinase (protein kinase B) negatively regulates GSK-3β to enhance the stability of the cyclin D-dependent kinase. 
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this regulatory machinery act as tumor suppressors or pro-
tooncogenes, whose mutations occur so frequently as to
prompt speculation that disabling “the RB pathway” may be
essential for the formation of cancer cells (Sherr, 1996; Sellers
and Kaelin, 1997; Nevins, 2001; Hahn and Weinberg, 2002;
Ortega et al., 2002). While RB disruption is the sine qua non of
retinoblastoma, RB loss occurs in many tumor types. Similarly,
although mutations inactivating p16INK4a function were first
mapped in familial melanoma (Kamb et al., 1994), they have
been cataloged in many other cancers (Ruas and Peters,
1998). Mutually exclusive events resulting in RB or p16INK4a inac-
tivation through mutation, deletion, or epigenetic silencing, or in
the overexpression of cyclin D1 or Cdk4, provide genetic evi-
dence for operation of this signaling pathway in tumor surveil-
lance.
Table 1 summarizes approximate frequencies of INK4a and
RB loss of function, and cyclin D1 or Cdk4 overexpression, in
different forms of cancer. It is notable that mutations affecting
the RB pathway generally occur in a mutually exclusive fashion,
so that one “hit” (e.g., INK4a mutation) is unaccompanied by
others (RB mutation or cyclin D-Cdk overexpression).
Interestingly, the frequency of particular genetic events varies
among tumor types. For example, in lung cancers, RB loss pre-
dominates in small cell tumors, whereas p16INK4a loss occurs in
the majority of non-small cell carcinomas. In addition, cervical
carcinomas and other squamous cell carcinomas frequently
express human papillomavirus (HPV) E7 proteins that target RB
family members. In cervical carcinomas that do not express
HPV E7, RB is inactivated by somatic mutation.
The cause of cyclin D1 overexpression in many tumor types
in unknown, although in mantle cell lymphomas, the cyclin D1
gene is juxtaposed to the immunoglobulin heavy chain promoter
enhancer via a t(11:14) translocation. This leads to ectopic
expression of cyclin D1 in B lymphocytes, which normally
express cyclins D2 and D3 preferentially. In contrast to p16INK4a
and RB, which seem to play specific roles in checkpoint control,
the selective involvement of particular D-type cyclins in tumori-
genesis may also reflect their normal patterns of tissue-specific
expression during development. Consistent with observations
that D1, and not D2 or D3, is the major D-type cyclin expressed
in both retinal and mammary epithelial tissues, mice lacking
cyclin D1 exhibit retinal hypoplasia and defective lobuloalveolar
development of breast epithelium during pregnancy (Fantl et al.,
1995; Sicinski et al., 1995). Conversely, enforced expression of
Figure 2. A G1 phase regulatory cascade
Cyclin D1 synthesis (step A) and assembly (step B) in response to mitogenic signals sequesters Cip/Kip proteins (p27Kip1 is shown) and relieves cyclin E-Cdk2
from their constraint. Both G1 cyclin-dependent kinases then collaborate to sequentially phosphorylate RB family proteins (only RB is shown) (step C). This
frees E2Fs from inhibition and leads to the activation of genes required for S phase entry (step D). Among the known E2F target genes is cyclin E, whose tran-
scriptional upregulation provides positive feedback to drive cells into S phase (step E). One substrate of cyclin E-Cdk2 is p27Kip1, whose phosphorylation trig-
gers its ubiquitination and degradation as cells enter S phase (step F).
Table 1. The RB pathway in human cancer
Cyclin D1 or 
Cancer type INK4a loss Cdk4 overexpression RB loss
Small cell 15% 5% Cyclin D1 80%
lung cancer
Non-small cell 58% 20%30%
lung cancer
Pancreatic cancer 80%
Breast cancer 30% >50% Cyclin D1
Glioblastoma 60% 40% Cdk4
multiforme
T cell ALL 75%
Mantle cell 90% Cyclin D1
lymphoma
This table summarizes approximate frequencies of Ink4a loss (by mutation,
deletion, or gene silencing), RB mutation or deletion, and cyclin D1 or Cdk4
overexpression in different forms of cancer.
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a cyclin D1 transgene in the breast tissue of mice predisposes
to mammary cancer (Wang et al., 1994). Moreover, whereas
mice overexpressing Her2/Neu or oncogenic Ras transgenes
targeted to mammary epithelium rapidly develop breast cancer,
they fail to do so in a cyclin D1 null background, indicating that
D1 function is essential for tumorigenesis and that other D-type
cyclins in breast tissue cannot compensate (Yu et al., 2001). In
contrast, mice overexpressing targeted Wnt or Myc oncogenes
develop breast carcinomas in a cyclin D1 null background,
apparently because these oncogenes induce cyclin D2 (Yu et
al., 2001).
The RB pathway is not strictly linear, in the sense that cyclin
D1 overexpression not only accelerates the RB-E2F transcrip-
tional program but also leads to p27Kip1 sequestration, thereby
lowering the Cdk2 threshold (Figure 2). Hence both RB and
p27Kip1 activity are negatively regulated by cyclin D1. The non-
catalytic role of cyclin D1 in sequestering p27Kip1 likely plays a
role in mammary tumorigenesis. In Her2/Neu transgenic mice,
mammary carcinoma is accelerated in a p27+/− genetic back-
ground but is inhibited in p27Kip1 null mice (Muraoka et al.,
2002). Thus, lowering the p27Kip1 threshold accelerates cancer
formation, presumably by relieving inhibition of Cdk2; however,
some residual p27Kip1 function is essential for tumor develop-
ment. Notably, cyclin D1-Cdk4 complexes could not stably
assemble in cultured mammary epithelial cells from p27Kip1 null
mice, but could reform when p27Kip1 was reintroduced (Muraoka
et al., 2002). These findings appear relevant to human breast
cancers where cyclin D1 is frequently overexpressed (Bartkova
et al., 1994) and where low levels of p27Kip1 convey a poor prog-
nosis (Catzavelos et al., 1997; Porter et al., 1997; Cariou et al.,
1998).
We still do not understand what particular selective advan-
tage accrues from disruption of the RB pathway. Cells lacking
RB or INK4a, or those overexpressing cyclin D1, do not divide at
an accelerated rate. On the other hand, blunted responses to
extracellular growth-inhibitory signals may prevent them from
terminally differentiating or undergoing senescence. As dis-
cussed below, disruption of the RB pathway initiates a compen-
satory p53-dependent transcriptional program that reinforces
cell cycle exit or, more dramatically, triggers apoptosis. In turn,
any subsequent failure of p53 function would allow such cells to
remain in cycle, abnormally extending cellular lifespan.
Interconnecting RB and p53
Surprisingly, the INK4a locus encodes a second gene product,
in part from an alternative reading frame that overlaps
sequences encoding p16INK4a (Quelle et al., 1995). The alterna-
tive reading frame protein (p19Arf in mice and p14ARF in humans)
is a potent tumor suppressor that activates p53 (Kamijo et al.,
1997). The p53 transcription factor is induced in response to
DNA damage, hypoxia, and oncogene activation, and it regu-
lates a program of gene expression that leads either to cell
cycle arrest or apoptosis (Levine, 1997; Giaccia and Kastan,
1998). Among the genes induced by p53 are the Cdk inhibitor
p21Cip1, many genes encoding proapoptotic proteins, and the
p53 negative regulator Mdm2 (Hdm2 in humans) that plays a
role in terminating the p53 response. Mdm2 binds directly to
p53 to inhibit transcription, and it catalyzes p53 ubiquitination,
targeting p53 for degradation (Juven-Gershon and Oren, 1999).
In turn, p19Arf binds directly to Mdm2 to antagonize these func-
tions (Sherr, 2001). The p53 gene is mutated in more than 50%
of human cancers, and mutations in other genes that affect p53
function occur in many, if not all, tumors that retain a normal p53
gene. Among these are mutations affecting Hdm2, ARF, and a
series of transcription factors that control ARF and p53 gene
expression.This points to another key signaling circuit in cancer
cells:
p14ARF/p19Arf | Hdm2/Mdm2 | p53
Both p53- and Arf-deficient mice spontaneously develop tumors
and die of cancers early in life (Jacks, 1996; Kamijo et al.,
1999a). Primary MEFs cultured from these animals do not
senesce in culture but instead yield immortal cell lines (Harvey
and Levine, 1991; Kamijo et al., 1997). In other mouse cell
types, both Arf loss and silencing of p16Ink4a are required for
establishment of cell lines, underscoring collaboration between
the RB and p53 pathways in this process (Holland et al., 1998;
Randle et al., 2001). Human fibroblasts also bypass senes-
cence when both the RB and p53 pathways are disabled, but
telomere shortening provides an additional barrier to immortal-
ization that must be overcome through reactivation of telomer-
ase or by telomere stabilization through alternative recombina-
tional mechanisms (Wright and Shay, 2000; Hahn and
Weinberg, 2002). These differences between human and
mouse cells reflect the presence of longer telomeres on mouse
chromosomes and the less active suppression of telomerase
activity in mouse versus human somatic cells. Hence, human
cells lacking intact RB and p53 checkpoints eventually experi-
ence telomere dysfunction, leading to chromosomal end-end
joining and fusion-bridge-breakage cycles that trigger the aneu-
ploidy observed in most carcinomas (Hanahan and Weinberg,
2000; Sherr and DePinho, 2000; Wright and Shay, 2000; Hahn
and Weinberg, 2002; O’Hagan et al., 2002 [this issue]).
The ability of deregulated E2F to induce ARF transcription
provides one connection between the RB pathway and p53
(DeGregori et al., 1997; Bates et al., 1998) and may help to
explain why most tumors have defects in the p53 pathway.
Overexpression of E2F in established cell lines lacking ARF or
p53 can enforce S phase entry even in the absence of mito-
genic stimulation (Johnson et al., 1993; Qin et al., 1994; Shan
and Lee, 1994), but nonimmortal human diploid fibroblasts
instead undergo an ARF-dependent p53 response leading to
G1 phase arrest and, later, to apoptosis (Lomazzi et al., 2002).
Enforced overexpression of p19Arf in primary MEFs induces cell
cycle arrest (Quelle et al., 1995), whereas induction of Arf by
ectopically expressed E2F1 or by certain oncoproteins, such as
Myc or adenovirus E1A (see below), is accompanied by apopto-
sis (De Stanchina et al., 1998; Zindy et al., 1998). Arf deficiency
partially protects cells from apoptosis induced by these pro-
teins. However, in mouse tumor models lacking functional RB or
overexpressing E2F, Arf loss does not invariably diminish apop-
tosis or accelerate tumorigenesis (Russell et al., 2002; Tolbert
et al., 2002; Tsai et al., 2002), indicating that E2F can activate
p53 through Arf-independent pathways. By interfering with
Mdm2, p19Arf enhances p53 stability and blocks cell prolifera-
tion, but further posttranslational modifications of p53 are likely
to be required for induction of the apoptotic program (Kamijo et
al., 1999b; Khan et al., 2000; Lin et al., 2001; Rogoff et al.,
2002). Understanding Arf dependency in some circumstances
and not others requires further investigation.
Further complexity stems from the fact that Rb-E2F acts
both upstream and downstream of the p19Arf-p53 axis. MEFs
lacking all three Rb family proteins do not senesce in culture
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and are resistant to p19Arf-induced cell cycle arrest
(Dannenberg et al., 2000; Sage et al., 2000). One possible inter-
pretation is that the antiproliferative activity of p19Arf might
strongly depend upon the ability of the p53-inducible Cdk
inhibitor, p21Cip1, to inhibit phosphorylation of Rb family mem-
bers. However, cells lacking Cip1 are not immortal and undergo
efficient p19Arf-induced arrest (Pantoja and Serrano, 1999;
Modestou et al. 2001). A mutant form of E2F (E2F-DB) that
binds to DNA but neither interacts with Rb nor transactivates
E2F target genes can displace Rb-E2F complexes from promot-
ers.When this mutant was overexpressed in primary MEFs, dis-
ruption of Rb-E2F-mediated repression increased the expres-
sion of E2F target genes, including Arf (Rowland et al., 2002).
Despite the activation of a persistent p19Arf-mediated p53
response, cells expressing E2F-DB were immortal and resistant
to ectopic overexpression of either p19Arf or p53. Therefore, Rb
(family)-E2F-mediated repression is required for cell cycle exit
in response to p19Arf-p53 activation. Defining the relevant E2F
target genes remains an open question, although genes encod-
ing functions necessary for S phase entry are reasonable can-
didates.
Arf is induced by abnormal mitogenic signals stemming
from activated or overexpressed oncoproteins such as Myc,
adenovirus E1A, mutated Ras, v-Abl, and β-catenin (Sherr,
2001). Activation of the Arf-Mdm2-p53 pathway reroutes cells
that have sustained oncogenic damage to alternative p53-
dependent fates—growth arrest or apoptosis (Figure 3).
Disruption of this pathway eliminates this form of tumor surveil-
lance and enables oncogenes to drive uncontrolled cell prolifer-
ation. By inducing Arf and Ink4a in primary rodent fibroblasts,
oncogenic Ras expression leads to growth arrest and prema-
ture senescence (Serrano et al., 1997; Ferbeyre et al., 2002).
However, Ras transforms established rodent cell lines lacking
Arf or p53 into tumor cells.
An independent Ras-activated pathway induces Mdm2 in
Arf null cells, which further dampens the p53 response and
makes such cells resistant to chemotherapeutic agents that
depend on p53 function to induce apoptosis (Ries et al., 2000).
Akt-mediated phosphorylation of Mdm2 enhances its nuclear
translocation and collaborates in destabilizing the p53 protein
(Mayo and Donner, 2001).
Overexpression of Myc in primary MEFs triggers apoptosis
and strongly selects for the appearance of surviving cells that
have lost either Arf or p53 function (Zindy et al., 1998). Mice
bearing a Myc transgene under the control of a B cell-specific
immunoglobulin promoter enhancer (Eµ-Myc) develop Burkitt-
type lymphomas with an average latency of six months (Adams
et al., 1985). In early stages of disease, increased S phase
entry by B cells in lymph nodes is counterbalanced by apoptosis
(Eischen et al., 1999; Schmitt et al., 1999). Eµ-Myc overexpres-
sion gradually selects for cells that lose Arf or p53 function, so
that the majority of lymphomas that arise bear such mutations
(Eischen et al., 1999). Crossing Eµ-Myc transgenic mice onto
an Arf+/− genetic background accelerates the formation of
tumors, most of which lose the wild-type Arf allele.The effects of
Eµ-Myc in Arf null mice are particularly dramatic, with all ani-
Figure 3. Cell autonomous tumor surveillance and therapeutic options
Mitogenic signaling activates E2Fs and Myc to advance cells into S phase. Stress signals that activate the Ink4a-Arf locus inhibit the activity of cyclin D-
dependent kinases (p16Ink4a) and induce p53 through either Arf-dependent or -independent pathways, reprogramming cells to undergo growth arrest or
apoptosis. Ras can also induce Mdm2 expression through a p53-independent pathway, further restraining the p53 response in Arf null cells. Protooncogenes
are shown in green and tumor suppressors in red. Sites for therapeutic intervention are indicated in blue.
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mals dying of aggressive lympholeukemias by only six weeks of
age.
Although Arf disruption accelerates Eµ-Myc-induced lym-
phomagenesis by blunting apoptosis, p16Ink4a loss does not;
strikingly, however, Ink4a mutations render mice resistant to
potentially curative chemotherapy (Schmitt et al., 2002). When
lymphomas arising in Eµ-Myc transgenic mice were transplant-
ed into cohorts of naive recipients, tumors lacking Ink4a-Arf
responded poorly to cyclophosphamide, whereas those lacking
Arf alone could be cured. In this setting, p16Ink4a and p53 collab-
orate to enable execution of a drug-induced senescence pro-
gram. This establishes different roles for Arf and Ink4a during
tumor development and indicates that p16Ink4a loss can interrupt
a genetic program that facilitates drug-induced cytostasis. Loss
of p53 portends a poorer prognosis, since p53 is required for
both apoptosis and cytostasis (Schmitt et al., 2002).
Susceptibility to familial melanoma was mapped to the
INK4a-ARF locus, and the critical mutations in some kindreds
affect p16INK4a but not p14ARF function (Kamb et al., 1994).
However, mice lacking Ink4a-Arf rarely develop melanoma
unless crossed with animals that express a Ras transgene in
appropriate target cells (Chin et al., 1997; Bardeesy et al.,
2001). When animals containing a mutant Ink4a allele were
crossed with mice lacking the entire Ink4a-Arf locus, heterozy-
gotes spontaneously developed melanomas, and dimethylben-
zanthrene treatment resulted in a higher frequency of aggres-
sive tumors (Krimpenfort et al., 2001). Thus, a subtle constella-
tion of genetic events involving p16Ink4a inactivation and Arf hap-
loinsufficiency programs a different outcome than complete loss
of Ink4a-Arf, which predisposes to other tumor types (Serrano
et al., 1996).
Although an abnormal threshold of mitogenic signals has
the potential to activate both Ink4a and Arf, neither gene is
broadly expressed at significant levels during fetal development
(Zindy et al., 1997). Bmi-1, a transcriptional repressor, actively
shuts off both genes, allowing rapid cell divisions to take place
in utero without activation of the RB and p53 checkpoints. Bmi-1
disruption leads to developmental anomalies in multiple organ
systems that are reversed on an Ink4a-Arf null background
(Jacobs et al., 1999a). As might be expected, then, overexpres-
sion of Bmi-1 accelerates Eµ-Myc-induced lymphomagenesis
by dampening p19Arf and p16Ink4a expression (Jacobs et al.,
1999b). Similarly, overexpression of other ARF repressors, such
as Twist and TBX2, occurs in several forms of human cancer
that retain wild-type p53 (Maestro et al., 1999; Jacobs et al.,
2000). Thus, tumors with normal ARF, Hdm2, and p53 genes
can still exhibit defective p53 function.
Opportunities for targeted therapy
Defects in apoptosis and cell cycle checkpoint control not only
affect tumor development, but also contribute to multidrug resis-
tance (Johnstone et al., 2002; Schmitt et al., 2002). How then
can we exploit known genetic defects in the RB and p53 path-
ways to rationally design effective anticancer treatment?
Therapies based on the RB pathway 
Disruption of cyclin D-Cdk complexes should prevent tumor pro-
gression in cases where specific D-type cyclins are overex-
pressed, or where “upstream” oncoproteins rely upon particular
D-type cyclins for their effects. Although most cell types synthe-
size more than one D-type cyclin and produce both Cdk4 and
Cdk6, the selective expression of cyclin D1 and Cdk4 in breast
epithelium (Fantl et al., 1995; Sicinski et al., 1995) and the strict
dependency on cyclin D1 for development of certain breast
tumors (Yu et al., 2001) argues for a role of cyclin D1 antagonists
in the treatment this disease. Since it remains unclear whether
the catalytic (Cdk activation) or stoichiometric (p27Kip1 sequestra-
tion) functions of cyclin D1 are required for breast tumorigenesis,
inhibitors that block cyclin D1 synthesis or assembly with Cdk4
would be ideal, since they would interfere with both processes.
However, preventing the assembly of cyclins with Cdks using
small molecules presents a formidable challenge, because of
the extensive interfaces that underlie their molecular interactions
(Pavletich, 1999). Another approach may be to interfere with
Ras-dependent kinase signaling cascades required for cyclin
D1-Cdk4 assembly. The Raf and PI3K signaling cascades that
govern cyclin D1 synthesis, stability, and Cdk assembly (Figures
1 and 3) are central to Ras-dependent antiapoptotic functions
and are themselves targets of oncogenic activation in many
tumor types. Hence, pharmacological development of selective
inhibitors of these pathways has long been underway, and many
are already in clinical trials for cancer treatment (Herrera and
Sebolt-Leopold, 2002). Cdk inhibitors (Gray et al., 1988; Hoessel
et al., 1999; Fry et al., 2001; Soni et al., 2001; Nahta et al., 2002)
might also prove useful in treating tumors that overexpress cyclin
D1-Cdk4 or that have lost INK4a function (Figure 3). However,
because certain Cdks play non-cell-cycle roles in processes
such as transcription and neural development, modulation of
Cdk function, if not highly specific, could well have unanticipated
side effects in nonproliferating cells (Sausville, 2002). Some
recently developed compounds exhibit more selectivity for Cdk4
and Cdk6 (Toogood, 2001), but target validation in vivo remains
a problem.
The adenovirus E1A protein binds to RB family proteins to
release E2Fs and promote S phase entry. Apart from activating
many E2F-responsive cellular genes, including E2F1 itself,
E2Fs regulate the E2 region of the adenoviral genome—
indeed, this is how E2F activity was first recognized. Moreover,
the E4 region of the adenovirus genome encodes a protein
(E4orf6/7) that binds directly to E2Fs, displacing RB and selec-
tively directing E2F to both the viral E2 promoter and to the cel-
lular E2F1 promoter. An adenovirus expressing a mutant form of
E1A that cannot bind RB should replicate selectively and kill
cells lacking functional RB (Fueyo et al., 2000). A variant in
which both the viral E4 and mutant E1A genes are placed under
the control of the human E2F1 promoter selectively kills tumor
cells with deregulated E2F, whereas normal cells halt viral repli-
cation in an RB-dependent manner (Johnson et al., 2002). Such
viruses are effective and relatively safe systemic antitumor
agents in xenograft models. Using additional variants with
increased potential for lysing cycling cells should provide even
further specificity and efficacy against tumor cells (Doronin et
al., 2000).
Increased E2F activity in tumor cells upregulates a number
of enzymes that are already targets for therapy. Indeed, classi-
cal anticancer agents such as methotrexate and 5-fluorouracil
act on E2F-regulated gene products (dihydrofolate reductase
and thymidylate synthase, respectively).These agents are often
effective, but patients become refractory, frequently through
mutations in the target genes. A complementary approach
might take advantage of synthetic lethality, in which disruption
of one of two genes that affect a vital function is compatible with
life, whereas loss of both causes cell death. For example, cells
that lack RB and manifest defects in E2F regulation are much
more sensitive than normal cells to cyclin A-Cdk2 inhibitors
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(Chen et al., 1999), which might show particular promise in
tumors with elevated E2F activity (Figure 3).
Therapies targeting the p53 pathway
Drugs and radiation commonly used in cancer treatment induce
p53 in normal tissues, contributing to their toxicity, whereas
tumors lacking p53 tend to resist drug-induced cell cycle arrest
and apoptosis (Johnstone et al., 2002). By screening a small
molecule library for inhibitors of p53-induced transcription,
Komarov and coworkers (1999) identified a compound that pro-
tected mice from the lethal effects of ionizing radiation. In princi-
ple, such a drug could be used to reduce the side effects of
chemotherapy, potentiating the efficacy of already available
agents.
Restoration of p53 function in p53 null tumors, which can
potentially be achieved through genetic or pharmacologic meth-
ods, can directly induce apoptosis and reestablish responses to
cytotoxic drugs (McCormick, 2001; Lane and Lain, 2002). Small
molecules that reactivate mutant p53, restoring its DNA binding
and transcriptional activity, were reported to exhibit antitumor
effects in vivo; these provide a novel approach not subject to
limitations of gene therapy (Foster et al., 1999). Instead of
replacing p53, it may be possible to identify compounds that
emulate the effects of certain p53 target genes in inducing cell
cycle arrest or apoptosis. For example, Cdk inhibitors (see
above) would be expected to mimic the effects of p21Cip1 on cell
cycle progression. Alternatively, it may be possible to engage an
extrinsic apoptotic program dependent on cell surface death
receptors, to which certain tumor types are particularly sensitive
(Ashkenazi et al., 1999).
Yet another approach utilizes lytic viruses to selectively kill
cells with defective p53 function. Adenoviruses must eliminate
p53 to replicate efficiently and do so by producing the E1B 55K
protein, which binds to p53 and helps target its destruction.
Adenoviruses that lack E1B 55K cannot replicate in cells that
retain normal p53 but lyse cancer cells that lack either p53 or
ARF function (McCormick, 2001). Patients with head and neck
cancer who were treated by direct injection of such viruses into
their tumor masses underwent limited clinical responses
(Nemunaitis et al., 2001), and more encouraging results of a
phase II trial in combination with 5-fluorouracil and cysplatin
have been reported (Khuri et al., 2000).
In tumors that retain wild-type p53, inhibitors of Hdm2 may
have therapeutic value. Introduction of p14ARF into such tumors
causes p53-dependent cytostasis or apoptosis, and small mole-
cule inhibitors of Hdm2 may have similar effects. Drugs that
block Hdm2 ubiquitin ligase activity, or peptides that prevent
Hdm2/p53 interaction, might offer similar advantages (Bottger
et al., 1996; 1997). In many tumors of this type, Hdm2 expres-
sion is regulated by the Ras/MEK/MAP kinase pathway. Drugs
that block this pathway are currently in clinical trials, and, in
experimental systems, inhibit Hdm2 expression and thereby
sensitize cells to p53-dependent apoptosis.This effect is tumor-
selective, as normal levels of Ras/MEK/MAP kinase signaling
do not affect p53 activity. Finally, p53’s ability to act as a tran-
scription factor is limited not only by Mdm2-directed p53 ubiqui-
tination but also by Mdm2-dependent nuclear export.
Leptomycin B, an inhibitor of CRM1-dependent nuclear trans-
port, activates p53 and exhibits some antitumor activity, but did
not show a sufficient therapeutic index in a phase I clinical trial
(Lane and Lain, 2002). Nonetheless, more selective drugs
affecting Mdm2-dependent nuclear export might have future
value.
Determining the genotypes of tumors and rationally design-
ing anticancer drugs based on defined targets should increase
treatment efficacy while decreasing toxicity. Although multiple
mutations contribute to malignancy, not all need to be corrected
to achieve significant therapeutic effects. Most attempts to treat
cancers in model systems through replacement of single tumor
suppressor genes or inhibition of individual oncogenes have
resulted in tumor killing or growth arrest. The dramatic success
of the Bcr-Abl kinase inhibitor Gleevec in treating chronic myel-
ogenous leukemia has greatly encouraged development of tar-
geted therapies (Druker, 2002), although the appearance of
drug resistance underscores the need for combinations of ther-
apies to achieve sustained remissions. Using combinations of
rational agents based on informed strategies should lead to
additional therapeutic successes without the traumatic side
effects of traditional anticancer regimens.
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